CD14 Activators
CD14 activators constitute a diverse array of chemical compounds strategically designed to directly enhance the functional activity of CD14, a pivotal component orchestrating the innate immune system's rapid responses. As an integral part of the immune system, CD14 plays a critical role in recognizing pathogen-associated molecular patterns (PAMPs), serving as a sentinel for the initiation of immune responses. The identified activators engage with specific signaling pathways and biological processes intricately associated with CD14, culminating in the augmentation of its functional activity. A notable subset of CD14 activators comprises bacterial components such as Lipopolysaccharide (LPS) and Monophosphoryl Lipid A (MPLA). These compounds activate CD14 through Toll-like receptor 4 (TLR4)-mediated signaling, thereby initiating downstream events involving NF-κB and MAPK pathways. The consequence is the heightened expression of pro-inflammatory cytokines, a hallmark of immune activation, and the potentiation of immune responses against invading pathogens.
Additionally, Pam3CSK4 and FSL-1 emerge as specific activators, engaging CD14-associated Toll-like receptor 2 (TLR2) signaling. This engagement leads to the modulation of innate immune processes, marked by the induction of pro-inflammatory cytokine production. Expanding the repertoire of CD14 activators, a group of compounds including Zymosan, Poly I:C, CpG Oligodeoxynucleotide (ODN), Flagellin, Imiquimod, Resiquimod, ODN 2006, and CL075 strategically target CD14-associated Toll-like receptors (TLR2, TLR3, TLR5, TLR7, TLR8, TLR9).
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
LPS activates CD14 by binding to its extracellular domain, triggering TLR4-mediated signaling. This leads to the activation of NF-κB and MAPK pathways, promoting the expression of pro-inflammatory cytokines. LPS, a component of Gram-negative bacteria, directly engages CD14, enhancing innate immune responses. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Pam3CSK4 activates CD14 by engaging TLR2, triggering downstream signaling events. This compound enhances the expression of pro-inflammatory cytokines through CD14-mediated pathways, contributing to the modulation of innate immune responses. Pam3CSK4 serves as a specific activator of CD14-associated TLR2 signaling. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $99.00 $599.00 | 1 | |
Zymosan activates CD14 through TLR2 and dectin-1, triggering immune responses. This compound enhances CD14-mediated signaling, leading to the activation of NF-κB and the production of pro-inflammatory cytokines. Zymosan, a fungal cell wall component, directly engages CD14 to modulate innate immune processes. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $663.00 | 2 | |
Poly I:C activates CD14-associated TLR3, inducing immune responses. This compound enhances CD14-mediated signaling, leading to the activation of NF-κB and the production of pro-inflammatory cytokines. Poly I:C, a synthetic double-stranded RNA analog, serves as a specific activator of CD14-associated TLR3 signaling. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod activates CD14-associated TLR7, promoting immune responses. This compound enhances CD14-mediated signaling, leading to the activation of NF-κB and the production of pro-inflammatory cytokines. Imiquimod, a synthetic imidazoquinoline, serves as a specific activator of CD14-associated TLR7 signaling. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Resiquimod activates CD14-associated TLR8, inducing immune responses. This compound enhances CD14-mediated signaling, leading to the activation of NF-κB and the production of pro-inflammatory cytokines. Resiquimod, a synthetic imidazoquinoline, serves as a specific activator of CD14-associated TLR8 signaling. | ||||||